|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
6.90/2.73
|
Enterprise Value
41.87B
|
Balance Sheet |
Book Value Per Share
16.18
|
Cash Flow |
Cash Flow Yield
0.02
|
Income Statement |
Total Revenue
6.00B
|
Operating Revenue Per Share
9.87
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/01/21 05:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US. |